Public Employees Retirement Association of Colorado Has $36.40 Million Stock Position in Pfizer Inc. (NYSE:PFE)

Share on StockTwits

Public Employees Retirement Association of Colorado decreased its stake in Pfizer Inc. (NYSE:PFE) by 0.3% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,013,065 shares of the biopharmaceutical company’s stock after selling 2,559 shares during the quarter. Public Employees Retirement Association of Colorado’s holdings in Pfizer were worth $36,399,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. Bath Savings Trust Co lifted its holdings in Pfizer by 3.4% during the second quarter. Bath Savings Trust Co now owns 17,217 shares of the biopharmaceutical company’s stock valued at $746,000 after purchasing an additional 564 shares in the last quarter. Cox Capital Mgt LLC increased its position in shares of Pfizer by 1.5% during the second quarter. Cox Capital Mgt LLC now owns 37,986 shares of the biopharmaceutical company’s stock valued at $1,646,000 after acquiring an additional 565 shares during the last quarter. Thomasville National Bank increased its position in shares of Pfizer by 4.1% during the second quarter. Thomasville National Bank now owns 76,628 shares of the biopharmaceutical company’s stock valued at $3,319,000 after acquiring an additional 3,001 shares during the last quarter. Park National Corp OH increased its position in shares of Pfizer by 27.6% during the second quarter. Park National Corp OH now owns 252,546 shares of the biopharmaceutical company’s stock valued at $10,941,000 after acquiring an additional 54,642 shares during the last quarter. Finally, Deane Retirement Strategies Inc. increased its position in shares of Pfizer by 1.8% during the second quarter. Deane Retirement Strategies Inc. now owns 51,699 shares of the biopharmaceutical company’s stock valued at $2,240,000 after acquiring an additional 894 shares during the last quarter. Institutional investors and hedge funds own 71.52% of the company’s stock.

In other news, Director Scott Gottlieb purchased 3,000 shares of the firm’s stock in a transaction that occurred on Friday, August 23rd. The stock was bought at an average price of $34.72 per share, for a total transaction of $104,160.00. Following the completion of the purchase, the director now directly owns 3,000 shares of the company’s stock, valued at $104,160. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Pfizer Inc purchased 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 17th. The stock was purchased at an average price of $18.00 per share, with a total value of $900,000.00. The disclosure for this purchase can be found here. 0.09% of the stock is owned by insiders.

Shares of NYSE PFE traded up $0.14 during midday trading on Friday, hitting $37.05. The company’s stock had a trading volume of 24,924,227 shares, compared to its average volume of 23,366,957. The business’s fifty day simple moving average is $36.62 and its two-hundred day simple moving average is $39.26. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.47 and a quick ratio of 1.21. Pfizer Inc. has a 1 year low of $33.97 and a 1 year high of $46.47. The firm has a market capitalization of $207.30 billion, a price-to-earnings ratio of 12.35, a price-to-earnings-growth ratio of 2.11 and a beta of 0.67.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.62 by $0.13. Pfizer had a net margin of 30.57% and a return on equity of 28.61%. The business had revenue of $12.68 billion during the quarter, compared to analyst estimates of $12.37 billion. During the same quarter last year, the firm posted $0.78 earnings per share. The business’s revenue for the quarter was down 4.6% compared to the same quarter last year. Analysts anticipate that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be paid a $0.36 dividend. The ex-dividend date is Thursday, November 7th. This represents a $1.44 dividend on an annualized basis and a yield of 3.89%. Pfizer’s dividend payout ratio is currently 48.00%.

PFE has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Pfizer in a research report on Tuesday, October 29th. Bank of America initiated coverage on shares of Pfizer in a research report on Wednesday, October 16th. They set a “neutral” rating and a $37.00 price target for the company. Morgan Stanley dropped their price target on shares of Pfizer from $40.00 to $38.00 and set an “equal weight” rating for the company in a research report on Tuesday, August 27th. DZ Bank raised shares of Pfizer from a “sell” rating to a “hold” rating and set a $36.00 price objective for the company in a research note on Wednesday, August 28th. Finally, Credit Suisse Group reissued a “hold” rating and issued a $41.30 price objective on shares of Pfizer in a research note on Wednesday. Nine investment analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $44.02.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Read More: What are benefits of a growth and income fund?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Putnam FL Investment Management Co. Has $424,000 Position in Magellan Midstream Partners, L.P.
Putnam FL Investment Management Co. Has $424,000 Position in Magellan Midstream Partners, L.P.
Eqis Capital Management Inc. Sells 824 Shares of Credit Acceptance Corp.
Eqis Capital Management Inc. Sells 824 Shares of Credit Acceptance Corp.
Eqis Capital Management Inc. Buys 10,007 Shares of Owens-Illinois Inc
Eqis Capital Management Inc. Buys 10,007 Shares of Owens-Illinois Inc
Axon Enterprise Inc  Shares Sold by Eqis Capital Management Inc.
Axon Enterprise Inc Shares Sold by Eqis Capital Management Inc.
Putnam FL Investment Management Co. Acquires 2,866 Shares of Vanguard Growth ETF
Putnam FL Investment Management Co. Acquires 2,866 Shares of Vanguard Growth ETF
Eqis Capital Management Inc. Reduces Holdings in Sprott Physical Silver Trust
Eqis Capital Management Inc. Reduces Holdings in Sprott Physical Silver Trust


 
© 2006-2019 Zolmax.